MNMotoi Nomura

Motoi Nomura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Motoi Nomura has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Population Pharmacokinetics and Detection Times of Betamethasone After Intravenous, Intramuscular, and Intranasal Jet Administration of Betamethasone Sodium Phosphate in Horses

    by Taisuke Kuroda, Marc Machnik, Mario Thevis, Yohei Minamijima, Gary Ngai‐Wa Leung, Motoi Nomura, Fumiaki Mizobe, Yuhiro Ishikawa, Kazuhiro Kamiya, Pierre‐Louis Toutain

    Betamethasone sodium phosphate (BETP) is a glucocorticosteroid used in humans. The primary objective was to estimate irrelevant plasma (IPC) and urine (IUC) concentrations using a pharmacokinetic/pharmacodynamic approach based on systemic clearance estimated from intravenous (IV) pharmacokinetic data. As a secondary objective, detection times (DTs) following IV, intramuscular (IM), and intranasal jet (INJ) administration were estimated for medication control. Plasma and urine concentrations were obtained from a total of 20 horses in Japan and Germany, with some horses contributing to more than one route after single IV (0.06 mg/kg, n = 7; 0.04 mg/kg, n = 8), single IM (20 mg/horse, n = 7), and multiple INJ (4 mg/horse for 5 days, n = 6) administration. The data were analyzed using a nonlinear mixed‐effects model. The plasma clearance was 276 mL/kg/h, and the steady‐state urine‐to‐plasma ratio was 25.8. For IV administration at 0.06 and 0.04 mg/kg every 24 h, the IPCs were 0.018 and 0.012 ng/mL, and the corresponding IUCs were 0.47 and 0.31 ng/mL, with the latter IUC close to the current International Federation of Horseracing Authorities international screening limit (ISL) (0.2 ng/mL). All horses fell below the ISL within 72 h after single IV administration at 0.06 and 0.04 mg/kg and after single IM administration, whereas all horses fell below the ISL within 48 h after INJ administration. The applicability of the estimated DTs should be interpreted according to the regulatory framework governing the use of human BETP formulations and their routes of administration in the relevant jurisdiction.

  • Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation

    by Taisuke Kuroda, Yohei Minamijima, Yuji Takahashi, Yusaku Ebisuda, Kaori Yoshida, Hiroshi Ishikawa, Kei‐Ichi Ishihara, Hiroshi Mita, Motoi Nomura, Toshio Nukada, et al.

    Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory E max model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC 50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06‐Hz reduction in DF. A model‐predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.

  • Open Access

    Biofilm-forming Ability and Antiseptic and Antimicrobial Susceptibility of Bacterial Strains Derived from Surgical-site Infections in Equine Orthopedic Surgery

    by Hiroshi Mita, Taisuke Kuroda, Motoi Nomura, M. Ohta

    Surgical site infection (SSI) is a serious complication of equine orthopedic surgery. Biofilm formation by the causative bacteria contributes to treatment failure by conferring tolerance to antimicrobial agents and disinfectants; however, data on biofilm formation and antiseptic or antimicrobial exposure in equine clinical isolates are limited.Our objectives were to evaluate the biofilm-forming ability of bacterial strains isolated from postoperative equine orthopedic SSI and to assess the susceptibility of established biofilms to disinfectants and antimicrobial agents after short-term exposure.A total of 102 bacterial strains were evaluated. Biofilms were formed using a 96-well plate with a peg-lid system, and biofilm biomass was quantified spectrophotometrically. Biofilms were exposed for 10 min to five agents at concentrations suitable for mucosal application in equine practice: povidone–iodine, chlorhexidine, benzalkonium chloride, gentamicin, and ampicillin. Viable bacteria were quantified by colony-forming unit counts, and effects were expressed as log reductions relative to controls.Biofilm-forming ability varied among bacterial groups, with Acinetobacter spp. showing the highest optical density (1.68 ± 0.91) and methicillin-sensitive Staphylococcus aureus exhibiting lower values (0.12 ± 0.08). Povidone–iodine showed high bactericidal activity across all bacterial groups (>5 log10 CFU reduction). In Gram-negative bacteria, it achieved significantly greater reductions than chlorhexidine and benzalkonium chloride (1–3 log10 CFU reduction). Antimicrobial agents showed no measurable bactericidal activity against established biofilms.Biofilm formation at surgical sites should be considered following equine orthopedic surgery. In this in vitro study, povidone–iodine had greater activity than other agents against established biofilms, suggesting its potential usefulness for biofilm-associated surgical site disinfection.

  • Open Access

    Effects of constant rate infusion of a fixed-dose combination of medetomidine and vatinoxan on cardiopulmonary function and gastrointestinal motility in standing Thoroughbred horses

    by Hiroshi Ishikawa, Hiroshi Ishikawa, Hiroshi Mita, Motoi Nomura, Keiichi Ishihara, Kazumichi Kodaira, Taisuke Kuroda, Minoru Ohta

    Background: A fixed-dose medetomidine (MED) and vatinoxan (VTX) combination has recently become commercially available. Unlike atipamezole (ATIP), VTX is a peripherally selective α2-adrenoceptor antagonist. MED–VTX administered as a constant rate infusion (CRI) may offer safer sedation for horses by reducing MED-associated peripheral adverse effects.Aims/objectives: To evaluate the sedative, cardiopulmonary, and gastrointestinal effects of MED–VTX or MED–ATIP, administered as a CRI, compared with MED alone in Thoroughbred horses.Methods: In this blinded three-way crossover study, six healthy Thoroughbreds received an intravenous (IV) bolus of MED (7 μg/kg), followed by 60-min CRI at 5 μg/kg/h. Group M (gM) received MED alone, Group MV (gMV) received MED + VTX (140 μg/kg IV, CRI at 100 μg/kg/h), and Group MA (gMA) received MED + ATIP (140 μg/kg IV, CRI at 100 μg/kg/h). Sedation was assessed using descriptive scales, including head height, stimulus response score and ataxia score. Heart rate (HR), respiratory rate (RR), arrhythmias, and defecation were recorded.Results: Compared with the gM, sedation scales were maintained in the gMV but were significantly reduced in the gMA. The HR and RR did not differ significantly among groups. Second-degree atrioventricular block was observed in one, five, and six horses in the gMV, gM, and gMA, respectively. Defecation occurred in all horses in the gMV (median: 2.5 times, range: 1–4 times) but none in the other groups.Conclusion: Continuous MED–VTX administration provides effective sedation while reducing proarrhythmic risk and gastrointestinal inhibitory effects in Thoroughbred horses.

  • Plasma and Urine Pharmacokinetics of Intravenous Pridinol in Thoroughbreds for Its Medication Control

    by Yohei Minamijima, Taisuke Kuroda, Atsushi Okano, Ai Wakuno, Reiko Yuasa, Yuhiro Ishikawa, Motoi Nomura, Kenji Kinoshita, Masayuki Yamada

    We examined the pharmacokinetics of intravenous pridinol in six thoroughbred horses. Each horse received a single 20 mg dose of pridinol mesylate via the jugular vein, and plasma and urine samples were collected over 72 h. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) was used to quantify pridinol concentrations in plasma and urine, allowing for the calculation of pharmacokinetic parameters. A three‐compartment model best fit the plasma elimination data. Using the Toutain model, irrelevant plasma and urine concentrations were estimated to be 0.00284 and 0.000612 ng/mL, respectively. Key pharmacokinetic parameters were clearance rate, 1.27 L/h/kg; steady‐state volume of distribution, 2.07 L/kg; and steady‐state urine‐to‐plasma ratio, 0.211. These findings can help establish regulatory thresholds for pridinol in horse racing and equestrian sports.

  • Pharmacokinetics of Salbutamol in Thoroughbred Horses After a Single Intravenous or Inhaled Administration

    by Motoi Nomura, Taisuke Kuroda, Minoru Ohta, Kanichi Kusano, Yohei Minamijima, Shunichi Nagata

    Salbutamol is a short‐acting and selective beta‐2 adrenergic agonist. Inhaled (IH) administration of salbutamol is widely used to control lower respiratory tract disease in horses. Here, we estimated the pharmacokinetic parameters of salbutamol after a single intravenous (IV) or IH administration in six horses, and we statistically analysed the detection times with various dosing regimens. Plasma and urine concentrations of salbutamol were measured by liquid chromatography–tandem mass spectrometry, and data were modelled by using a nonlinear mixed effect model followed by Monte Carlo simulation (MCS). With IH salbutamol, the maximum plasma concentration was 0.12 ± 0.06 ng/mL at 0.29 ± 0.17 h after administration. Typical values were, for clearance, 1.53 L/kg/h; distribution volume at steady state, 5.43 L/kg; terminal half‐life, 6.06 h; IH bioavailability, 19.0%; and urine to plasma ratio, 2057. Statistically estimated 95th percentile detection times in the urine at levels below the international screening limit (0.5 ng/mL) proposed by the International Federation of Horseracing Authorities, as simulated in 5000 horses by MCS, were 44 h after 1.6 μg/kg q 24 and 54 h after 1.6 μg/kg q 4 h over a 3‐day IH administration period.


  • Quantification of osilodrostat in horse urine using LC/ESI–HRMS to establish an elimination profile for doping control

    by Hideaki Ishii, Ryo Shigematsu, Shunsuke Takemoto, Yuhiro Ishikawa, Fumiaki Mizobe, Motoi Nomura, Daisuke Arima, Hirokazu Kunii, Reiko Yuasa, Takashi Yamanaka, et al.

    Aim: The use of osilodrostat, developed as a medication for Cushing's disease but categorized as an anabolic agent, is banned in horses by both the International Federation of Horseracing Authorities and the Federation Equestre Internationale. For doping control purposes, elimination profiles of hydrolyzed osilodrostat in horse urine were established and the detectability of free forms of osilodrostat and its major metabolite, mono-hydroxylated osilodrostat (M1c), was investigated. Materials & methods: Post-administration urine samples obtained from a gelding and three mares were analyzed to establish the elimination profiles of osilodrostat using a validated method involving efficient enzymatic hydrolysis followed by LC/ESI-HRMS analysis. Results: Applying the validated quantification method with an LLOQ of 0.05 ng/ml, hydrolyzed osilodrostat could be quantified in post-administration urine samples from 48 to 72 h post-administration; by contrast, both hydrolyzed osilodrostat and M1c were detected up to 2 weeks. In addition, confirmatory analysis identified the presence of hydrolyzed osilodrostat for up to 72 h post-administration. Conclusion: For doping control purposes, we recommend monitoring both hydrolyzed M1c and osilodrostat because of the greater detectability of M1c and the availability of a reference material of osilodrostat, which is essential for confirmatory analysis.

  • Metabolic Pathway of Osilodrostat in Equine Urine Established through High-resolution Mass Spectrometric Characterization for Doping Control

    by Hideaki Ishii, Ryo Shigematsu, Shunsuke Takemoto, Yuhiro Ishikawa, Fumiaki Mizobe, Motoi Nomura, Daisuke Arima, Hirokazu Kunii, Reiko Yuasa, Takashi Yamanaka, et al.

    Objective: Osilodrostat, used to treat Cushing's disease, exhibits an anabolic effect, leading to its classification as a prohibited substance in horseracing and equestrian sports. This study reports the characterization of osilodrostat metabolites in horse urine and elucidates its metabolic pathways for the first time for doping control purposes. Methods: Osilodrostat was administered nasoesophageally to four thoroughbreds (one gelding and three mares) at a dose of 50 mg each. Potential metabolites were extensively screened via our developed generic approach employing differential analysis to identify metabolites. Specifically, high-resolution mass spectral data were compared between pre- and post-administration samples on the basis of criteria of fold-changes of peak areas and their P values. Potential metabolite candidates were further identified through mass spectral interpretations using product ion scan data. Results: A total of 37 metabolites were identified after comprehensive analysis. Osilodrostat was predominantly metabolized into a mono-hydroxylated form M1c (~40%) alongside osilodrostat glucuronide M2 (~17%). Given their longest detection time (2 weeks after administration) and the identification of several conjugates of osilodrostat and M1c, including a novel conjugate of riburonic acid, we recommend monitoring both osilodrostat and M1c after hydrolysis during the screening stage. However, only osilodrostat can be used for confirmation because of the availability of a reference material. Conclusion: It is advisable to screen for both osilodrostat and its mono-hydroxylated metabolite M1c to effectively monitor horse urine for the potential misuse or abuse of osilodrostat. For suspicious samples, confirmation of osilodrostat using its reference material is required.